Just when you had written off biotech stocks as boring, here comes the MIT Technology Review to name its “Three technologies that will shape biotech in 2026.” There’s no moonshot cure for cancer expected just yet, but we can apparently look forward to personalized gene editing; gene resurrection; and even designer babies. (And yes, those of us who recall the more visceral lessons of films like Jurassic Park and The Boys from Brazil might be justified in a double take.)
While much of the focus – and controversy – around artificial intelligence (AI) technology has centered on specialized semiconductors and the resource-hungry data centers they power, many analysts are starting to turn their attention to another market segment that’s tapping heavily into AI's potential: the biotechnology sector.
